Bispecific Antibody Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Epcoritamab is for patients who have received two or more lines of systemic therapy
Source: medpagetoday.com
Page 5 - Tycel Phillips News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tycel Phillips. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tycel Phillips Today - Breaking & Trending Today
FDA Approves Epkinly for Relapsed/Refractory DLBCL
The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.
Source: curetoday.com
City of Hope researchers present innovative studies at American Society of Hematology (ASH) Annual Meeting
/PRNewswire/ -- Doctors and scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, presented data...
Source: prnewswire.com
Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody
Most complete responses lasted 24 months or longer after limited-duration glofitamab
Source: medpagetoday.com
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual
Source: finanznachrichten.de